[4-(3-hydroxyphenyl)-8-(trifluoromethyl)quinolin-3-yl](phenyl)methanone | 854765-81-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: [4-(3-hydroxyphenyl)-8-(trifluoromethyl)quinolin-3-yl](phenyl)methanone
• 英文别名: [4-(3-hydroxyphenyl)-8-(trifluoromethyl)quinolin-3-yl]-phenylmethanone
• CAS: 854765-81-4
• 化学式: C₂₃H₁₄F₃NO₂
• 分子量: 393.365
• InChiKey: KENBGHMSTBKWSA-UHFFFAOYSA-N

物化性质

• 熔点：
  213-215 °C
• 沸点：
  575.1±50.0 °C(Predicted)
• 密度：
  1.346±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [4-(3-hydroxyphenyl)-8-(trifluoromethyl)quinolin-3-yl](phenyl)methanone 在 sodium hydroxide 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 丙酮 为溶剂， 反应 4.0h， 生成 4-({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}methyl)benzoic acid
  参考文献：
  名称：

  Discovery of Phenyl Acetic Acid Substituted Quinolines as Novel Liver X Receptor Agonists for the Treatment of Atherosclerosis

  摘要：

  A structure-based approach was used to optimize our new class of quinoline LXR modulators leading to phenyl acetic acid substituted quinolines 15 and 16. Both compounds displayed good binding affinity for LXR beta and LXR alpha and were potent activators in LBD transactivation assays. The compounds also increased expression of ABCA1 and stimulated cholesterol efflux in THP-1 cells. Quinoline 16 showed good oral bioavailability and in vivo efficacy in a LDLr knockout mouse model for lesions.

  DOI：

  10.1021/jm0609566
• 作为产物：
  描述：

  邻氨基三氟甲苯 在 四(三苯基膦)钯 potassium phosphate 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 乙醚 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 43.0h， 生成 [4-(3-hydroxyphenyl)-8-(trifluoromethyl)quinolin-3-yl](phenyl)methanone
  参考文献：
  名称：

  Discovery of Phenyl Acetic Acid Substituted Quinolines as Novel Liver X Receptor Agonists for the Treatment of Atherosclerosis

  摘要：

  A structure-based approach was used to optimize our new class of quinoline LXR modulators leading to phenyl acetic acid substituted quinolines 15 and 16. Both compounds displayed good binding affinity for LXR beta and LXR alpha and were potent activators in LBD transactivation assays. The compounds also increased expression of ABCA1 and stimulated cholesterol efflux in THP-1 cells. Quinoline 16 showed good oral bioavailability and in vivo efficacy in a LDLr knockout mouse model for lesions.

  DOI：

  10.1021/jm0609566

文献信息

• Quinolines useful in treating cardiovascular disease
  申请人：Collini D. Michael

  公开号：US20050131014A1

  公开（公告）日：2005-06-16

  This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

  本发明提供了式I化合物的用途，它们在治疗或抑制LXR介导的疾病中是有用的。
• Quinolines and pharmaceutical compositions thereof
  申请人：Wyeth

  公开号：US07576215B2

  公开（公告）日：2009-08-18

  This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

  本发明提供了I式化合物，可用于治疗或抑制LXR介导的疾病。
• QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE
  申请人：Wyeth, A Corporation of the State of Delaware

  公开号：EP1692111A2

  公开（公告）日：2006-08-23
• US7576215B2
  申请人：——

  公开号：US7576215B2

  公开（公告）日：2009-08-18
• [EN] QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE<br/>[FR] QUINOLINES CONVENANT POUR LE TRAITEMENT DE MALADIES CARDIO-VASCULAIRES
  申请人：WYETH CORP

  公开号：WO2005058834A2

  公开（公告）日：2005-06-30

  This invention provides compounds of formula (I) that are useful in the treatment or inhibition of LXR mediated diseases.